ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc (MIRM)

37.90
-2.39
(-5.93%)
At close: September 18 4:00PM
37.90
-0.03
( -0.08% )
After Hours: 6:05PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
37.90
Bid
37.00
Ask
37.99
Volume
1,497,985
36.8591 Day's Range 40.55
23.14 52 Week Range 45.23
Market Cap
Previous Close
40.29
Open
40.33
Last Trade Time
16:53:18
Financial Volume
$ 57,730,095
VWAP
38.5385
Average Volume (3m)
539,402
Shares Outstanding
47,707,204
Dividend Yield
-
PE Ratio
-11.07
Earnings Per Share (EPS)
-3.43
Revenue
186.37M
Net Profit
-163.42M

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $40.29. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.14 to $ 45.23.

Mirum Pharmaceuticals currently has 47,707,204 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.92 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.07.

Mirum Pharmaceuticals (MIRM) Options Flow Summary

Overall Flow

Bearish

Net Premium

-40k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

MIRM Latest News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC...

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the...

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.05-9.6543504171641.9542.4937.927977140.90295871CS
4-3.08-7.515861395840.9845.2337.934068541.85466243CS
124.8114.536113629533.0945.2332.3453940239.87080423CS
2611.443.018867924526.545.2323.1458058532.58686809CS
524.9615.057680631532.9445.2323.1457998030.99670582CS
15619.66107.78508771918.2445.2312.8242713226.86740847CS
26028.47301.9088016979.4345.236.512630660625.43426054CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
XCURExicure Inc
$ 5.715
(149.56%)
7.99M
VEROVenus Concept Inc
$ 1.13
(124.88%)
13.39M
ZEOZeo Energy Corporation
$ 1.58
(38.60%)
103.2k
TBIOTelesis Bio Inc
$ 1.65
(21.32%)
758.37k
RELIReliance Global Group Inc
$ 3.07
(18.08%)
202.33k
SMFLSmart for Life Inc
$ 0.43
(-44.87%)
2.34M
PGNYProgyny Inc
$ 18.9885
(-22.31%)
131.61k
RGFReal Good Food Company Inc
$ 0.3701
(-13.93%)
28.2k
CRMTAmericas Car Mart Inc
$ 43.75
(-12.43%)
7k
OMEXOdyssey Marine Exploration Inc
$ 1.25
(-10.71%)
4.66M
VEROVenus Concept Inc
$ 1.13
(124.88%)
13.39M
XCURExicure Inc
$ 5.715
(149.56%)
7.99M
EJHE Home Household Service Holdings Ltd
$ 0.1148
(8.30%)
7.56M
NVDANVIDIA Corporation
$ 113.68
(0.27%)
6.19M
OMEXOdyssey Marine Exploration Inc
$ 1.25
(-10.71%)
4.66M

Your Recent History

Delayed Upgrade Clock